Home Tags NBE-Therapeutics

Tag: NBE-Therapeutics

Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Steffen Heeger, MD, Ph.D to Lead NBE-Therapeutics’ Clinical iADC Development

Privately-owned Swiss, Basel-based, NBE-Therapeutics has appointed Steffen Heeger MD, Ph.D. as Chief Medical Officer to lead the clinical development of NBE-002, the company's first...

WuXi Biologics and NBE-Therapeutics Collaborate in Development and Manufacturing Partnership

WuXi Biologics, an open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Swiss biotech NBE-Therapeutics, developing best-in-class, next-generation...

NBE Therapeutics Receives Additional Series B Financing – Supports Clinical Testing...

Novo Holdings, a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, manages the Foundation's investment assets. Earlier this year, the...

PepTalk 2017: Antibody-drug Conjugates and the Promise of Innovation

ADC or antibody-drug conjugates have recently been at the forefront of cancer research, and according to the experts presenting their latest data during the...

NBE Therapeutics and SOTIO Collaborate in the Development of the Next-Gen...

NBE Therapeutics, a privately owned Swiss, Basel-based Biotech company, and SOTIO, a biotechnology company located in Prague, Czech Republic, with facilities in Europe, the United...

London Calling: The Cutting-edge of Novel ADC Technologies

Major players in the rapidly advancing field of antibody drug conjugates (ADCs) will meet in London, United Kingdom, on 23-24 May for the annual...

FEATURED RESOURCES